Navigation Links
Novartis to Expand Global Research Headquarters in Cambridge, MA
Date:10/27/2010

expected research and developed difficulties or delays; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisNovartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more infor
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... -,Phytopharm plc (LSE: PYM) ("Phytopharm" or the ... reverses the,changes in the area of the ... be presented by Dr Jonathan Brotchie, an,internationally ... International Congress of Parkinson's Disease and Movement,Disorders' ...
... UVIDEM was well-tolerated with signs of durable,disease control ... 05, 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented ... vaccine clinical trial (DC-MEL-202). The,results showed that UVIDEM ... of immune response in patients with,progressive metastatic melanoma. ...
Cached Medicine Technology:Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 2Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 3Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 4Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 5IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5
(Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... relief targets that could be used to provide ... College London made the discovery when researching how ... the body. , Dr Marzia Malcangio said: "We ... generation and our findings could help chemotherapy patients ... potential side effect of some chemotherapy drugs (such ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... researchers at Mayo Clinic shows that obese patients with ... loss drug sibutramine, while others who lack these genetic ... are published in the October issue of Gastroenterology ... placebo-controlled study, Mayo researchers measured the impact of two ...
... who are part of an Asian-white ,couple face an ... in which both partners are white, according to a new ... University ,School of Medicine. , The researchers also found ... likely than white women with Asian or white partners to ...
... to help save more than 1 million children, Stores ... N.J., Sept. 30 Quarters found in the,bottom of purses, ... living and dying for needy children. The Vitamin Shoppe is ... save the life of a,child., Affecting up to 140 ...
... Turns to Medical Professional to Apply Rigors,of "Evidence-Based Medicine" ... Give Bad Advice About the Best Medicine For Portfolios?, ... expected to base their diagnoses on what the latest ... specific diseases and other,illnesses. Yet most financial advisors do ...
... Hits $178 Million Mark, WHITE PLAINS, N.Y., Sept. ... it has awarded a new Marshall A. Lichtman,Specialized Center ... Becker Professor of Medicine at Stanford University., Dr. ... year for five,years, for a total of $6.25 million. ...
... presidential debate history, a female nominee will take the stage ... new ground in 1984, it has taken 24 years for ... party ticket. On Thursday night, the nation will be watching ... in the vice presidential debate. A revealing study by a ...
Cached Medicine News:Health News:Genes affect weight loss drug effectiveness 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 3Health News:Spare Change Can Help Save the Life of a Child 2Health News:Spare Change Can Help Save the Life of a Child 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 2Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 4Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 5Health News:The Leukemia & Lymphoma Society Awards Major Grant to Stanford Researcher 2Health News:Gender is a relative term in politics, MU study finds 2
... MonoPrep LBP Processor is a primary component ... collection, accessioning, processing, sampling, and slide preparation ... management. The MonoPrep LBP Processor produces high-quality ... a broad range of cytology specimen types. ...
... quick and easy automated refill system ... space on your laboratory bench and ... easy-to-use, one-hand system, you only need ... of Diamond Tips. All sizes of ...
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
Medicine Products: